This paper is in the following e-collection/theme issue:

Behavioural Surveillance for Public Health (215) Longitudinal and Cohort Studies in Public Health (276) Reviews on Cardiovascular Health and Medicine (26) Diabetes Reviews and Scoping Studies (31) Cardiovascular Disease Prevention (121)

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54318, first published .
Dose-Response Relationship Between Physical Activity and the Morbidity and Mortality of Cardiovascular Disease Among Individuals With Diabetes: Meta-Analysis of Prospective Cohort Studies

Dose-Response Relationship Between Physical Activity and the Morbidity and Mortality of Cardiovascular Disease Among Individuals With Diabetes: Meta-Analysis of Prospective Cohort Studies

Dose-Response Relationship Between Physical Activity and the Morbidity and Mortality of Cardiovascular Disease Among Individuals With Diabetes: Meta-Analysis of Prospective Cohort Studies

Authors of this article:

Yang Chen1 Author Orcid Image ;   Xingsheng Jin1 Author Orcid Image ;   Guochong Chen2 Author Orcid Image ;   Ru Wang1 Author Orcid Image ;   Haili Tian1 Author Orcid Image
Article Authors Cited by Tweetations Metrics

    Original Paper

    1School of Exercise and Health, Shanghai University of Sport, Shanghai, China

    2Department of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, China

    Corresponding Author:

    Haili Tian, PhD

    School of Exercise and Health

    Shanghai University of Sport

    Yangpu District Qingyuan Huan Road 650

    Shanghai, 200438

    China

    Phone: 86 13512281696

    Email: tianhaili123@163.com


    Background: Diabetes, a chronic condition affecting various organs, is frequently associated with abnormal lipid metabolism, notably increased cholesterol and triglyceride levels. These lipid abnormalities are closely linked to the development and advancement of cardiovascular disease (CVD). Although regular physical activity (PA) has consistently shown benefits in reducing CVD risk in the general population, its precise influence on CVD risk among patients with diabetes remains uncertain, particularly regarding dose-response relationships.

    Objective: This study aimed to summarize the evidence from prospective studies on the association between PA and CVD morbidity and mortality in individuals with diabetes and explore the optimal levels for public health recommendation.

    Methods: We systematically reviewed prospective cohort studies in PubMed, Embase, and Web of Science up to December 2022, with inclusion criteria specifying the studies published in English and included adult participants diagnosed with diabetes. A random effects model was used to pool the relative risk (RR) with the corresponding 95% CI comparing the highest with the lowest PA categories in each study for qualitative evaluation. In addition, linear and spline regression analyses were used to estimate dose-response associations.

    Results: The meta-analysis included 12 prospective cohort studies, involving a total of 109,820 participants with diabetes. The combined results revealed that higher levels of PA were associated with a reduced risk of CVD. The RR of CVD for the highest compared with the lowest PA category was 0.62 (95% CI 0.51-0.73). In addition, there were 4 studies describing leisure-time PA, and the pooled RR was 0.68 (95% CI 0.52-0.83) for the highest versus the lowest activity. The linear regression model revealed that each 10 MET (metabolic equivalent of task)-hours per week of incrementally higher PA was associated with a 19% (95% CI 11.6-25.7) and a 6.9% (95% CI 4.5-9.3) reduction in CVD morbidity and mortality. Additionally, spline regression curves showed nonlinear relationships between PA levels and the risk of CVD and CVD mortality (both Pnonlinearity<.001), with a limited reduction in CVD risk and some further reduction in CVD mortality above 20 MET-hours per week of PA levels.

    Conclusions: For patients with diabetes, especially type 2 diabetes, there was a dose-response relationship between increased PA and reduced risk of CVD morbidity and mortality. The observed PA threshold is consistent with the recommended level for the general population. Gradually moving from inactivity to a guideline-recommended PA level could therefore significantly reduce the burden of CVD in patients with diabetes.

    JMIR Public Health Surveill 2024;10:e54318

    doi:10.2196/54318

    Keywords

    cardiovascular risk; diabetics; exercise; dose-response association; meta-analysis; physical activity; diabetes 


    Diabetes, as a chronic disease, poses a significant risk to the functionality of multiple organs. Alongside the impairment of nerves and blood vessels, diabetes can lead to various severe complications, including retinopathy, nephropathy, and diabetic foot ulcers [1-3]. Data from the International Diabetes Federation showed that 6.7 million people died from diabetes in 2019, and 1 in 10 adults aged 20-79 years had diabetes, totaling 537 million people [4]. Medical spending on diabetes accounts for 9% of the global health spending, totaling US $966 million. By 2045, there will be an increase of 3.6 million people with diabetes worldwide, and the increase in diabetes-related health expenditures will exceed 206 billion, and the number of people who will die from diabetes will increase by 2.5 million [5,6]. Patients with diabetes often exhibit abnormal lipid metabolism, including elevated levels of cholesterol and triglycerides [7]. These abnormal lipid levels are closely associated with the occurrence and progression of cardiovascular disease (CVD) [8]. CVD is a group of diseases caused by atherosclerosis, characterized by lipid deposition and plaque formation on the arterial walls, ultimately leading to vascular narrowing and obstruction [9]. In patients with diabetes, abnormal lipid metabolism accelerates the progression of atherosclerosis, thereby increasing the risk of cardiovascular events such as myocardial infarction and stroke [10]. According to the latest guidelines, adults with diabetes face 2-3 times the risk of developing CVD [11]. The risk of atrial fibrillation in patients with diabetes increases by 3%, leading to higher possibilities of stroke, heart failure, and mortality [11]. CVD remains a leading cause of death worldwide, resulting in approximately 20.5 million fatalities and accounting for one-third of the total global mortality [12,13].

    The beneficial role of regular physical activity (PA) in reducing the risk of CVD has been repeatedly confirmed in the general population [14-17]. Through PA, patients with diabetes can gradually establish a healthy lifestyle, thereby improving overall health and reducing the risk of chronic diseases [18]. Regular PA has the potential to enhance insulin sensitivity, improve vascular responsiveness, and optimize cardiorespiratory fitness levels [19-21]. These physiological adaptations may contribute to a reduced incidence of CVD among individuals living with diabetes [22]. The health benefits of PA in individuals with diabetes are mentioned in existing guidelines and public health recommendations. For example, the European Society of Cardiology guidelines for PA in patients with cardiac conditions mentioned the benefits of aerobic exercise and strength training for patients with diabetes for blood glucose and blood pressure control, weight loss and improved exercise capacity, as well as increased exercise capacity and reduced risk of CVD [23]. The World Health Organization [24] recommends that 150-300 minutes of moderate to vigorous PA per week is also applicable to adults with chronic diseases such as diabetes.

    However, previous prospective studies have yielded inconsistent results regarding the relationship between PA levels and CVD risk in patients with diabetes. Some literature highlights the health benefits of moderate to high PA levels in reducing CVD risk, particularly at the moderate level [5,25]. Conversely, another study suggests that the association between changes in PA levels and CVD risk factors among patients with diabetes is relatively weak, implying a limited direct impact on cardiovascular health [26]. Consequently, the dose-response relationship between PA and CVD risk remains unclear, requiring additional research for informed public health recommendations.

    The primary objective of this meta-analysis was to synthesize evidence from prospective studies to elucidate the relationship between PA and CVD in patients with diabetes. Additionally, we aimed to quantify the weekly metabolic equivalent of task (MET) for PA exposure and clarify the dose-response relationship. This study aimed to provide a theoretical foundation for future exercise prescriptions for individuals with diabetes, ultimately improving health outcomes in this patient population.


    Ethical Considerations

    This review paper presents a secondary analysis of existing data from previously published original studies rather than a direct collection of new data. As such, ethics approval was not necessary.

    Search Strategy

    Electronic literature searches were conducted for cohort studies investigating the association between PA and CVD risk among individuals with diabetes. The searches were performed from inception to December 2022 for relevant studies published in MEDLINE, Embase, and the Web of Science. The study keywords used in the searches were thesaurus terms registered in MEDLINE (MeSH) or Embase (EMTREE), as well as entry words related to diabetes, PA, CVDs, and cohort study.

    Inclusion and Exclusion Criteria

    The inclusion and exclusion criteria for the study are shown in Textbox 1.

    Textbox 1. The inclusion and exclusion criteria for the study.

    Inclusion criteria

    • Paper type: prospective cohort study.
    • Population: adult patients with diabetes.
    • Disease: outcomes are cardiovascular diseases, including fatal and nonfatal cardiovascular events.
    • Methods: studies that provide or allow for the calculation of effect size (ie, relative risk, hazard ratio, or odds ratio) and corresponding SE for high physical activity (PA) categories compared with the lowest PA category.
    • Language: studies in the English language.

    Exclusion criteria

    • Paper type: presence of additional nonpharmacological interventions.
    • Methods: studies lacking effect sizes or where calculation is not feasible. No stratified comparison of PA.
    • Language: languages other than English.

    Selection Process

    The titles and abstracts of a large number of publications were obtained using the aforementioned search strategy. These papers were divided equally between the 2 authors (YC and XJ) and initially screened based on the titles. Subsequently, the third author (HT) cross-checked 1100 (15%) of the 7334 documents to ensure accuracy for initial inclusion. The abstracts of the initially included studies were then read independently by both authors (YC and XJ) for inclusion. Any disagreements were referred to the third author (GC) and resolved through discussion. Finally, 1 author (RW) reviewed the full papers, and the second author (HT) cross-checked the included literature to determine the final inclusion criteria.

    Data Extraction

    The 2 authors (YC and XJ) independently extracted the key characteristics of the included studies, and discrepancies were resolved through discussion. When multiple effect measures, such as unadjusted and adjusted measures, were present in the included studies, the most fully adjusted measures were selected. The key characteristics of the research included, but were not limited to, the author, year of publication, study population, person-years, follow-up time, cohort status, disease diagnosis methods, and methods of measuring PA.

    Assessment of Study Quality

    A quality criteria scale was developed at the study level using applicable elements from the Newcastle-Ottawa scale for cohort studies. This scale has been widely used in meta-analyses of exercises and health risks. The study-level quality assessment was conducted by 2 authors (HT and RW).

    Data Analysis

    To assess the qualitative association between PA and CVD risk, we pooled the log relative risk (RR) of the highest versus the lowest PA categories from each study using the inverse variance method. Heterogeneity among the studies was evaluated using Q statistics and I2, both overall and within each stratum after stratification [27]. If significant between-study heterogeneity was observed, a random effects model was used to calculate the pooled estimate [28].

    We also conducted subgroup analyses to explore differences between subgroups to search for possible effect modifiers or sources of heterogeneity. To verify possible sources of heterogeneity, stratified analyses were conducted on the following study characteristics that we identified based on previously extracted data from the included studies: mean follow-up duration (≤10 years or >10 years), type of diabetes (1 or 2), diabetes duration (not available, ≤10 years or >10 years), mean age (<60 years or ≥60 years), PA type (total PA or leisure-time PA), the proportion of men (≤50% or >50%), validation of PA questionnaire (no or yes), area (Asia or Europe or North America or mixtures), and mean BMI (≤25, 25, or ≤30 kg/m2) [29]. Meta-regression analysis was used to test differences between these strata.

    Publication bias was primarily detected by visual assessment using funnel plots in which SE was plotted against log RR for the highest and lowest PA categories in each study. Symmetry in the plot was assumed to indicate no publication bias. In addition, a statistical assessment using the Egger regression asymmetry test confirmed the symmetry [30]. To assess the robustness of our findings, we performed a sensitivity analysis by systematically omitting 1 study at a time to evaluate its impact on the overall pooled results.

    We extracted detailed information from the literature that quantified PA in subsequent dose-response analysis studies. If the graded quantification of PA in a paper was not a point estimate, we assumed a consistent width for each category of PA and considered the middle value of its upper and lower limits as the point estimate of PA for this category [31]. The same standard unit (MET-hours) was used to standardize the PA doses reported in the literature.

    PA is represented by different forms of exercise, such as walking, running, moderate to vigorous exercise, and sedentary activities. For some studies that did not directly give the corresponding quantitative data, we defined the data according to the compendium, such as for different exercise intensities, using 1.0-1.5, 1.6-2.9, 3-5.9, and ≥6 MET [32]. Following the above expression, we translate it into the corresponding point estimates: 1.5, 4.5, and 7.5 MET. If the literature only stated the average duration of a given exercise, we assumed that the individuals performed it at an intensity of 4.5 MET [33,34].

    First, we assumed a log-linear relationship between PA and CVD morbidity and mortality. To investigate this relationship, we used a weighted least squares regression model. In addition, we used restricted cubic spline regression models to further explore the shape of the relationship between PA and CVD outcomes. In both models, we regressed of the log RR for each nonreferent group against a higher dose of PA compared to the lowest PA category. Data analysis was conducted using STATA software (version 17; StataCorp LLC). We considered a 2-sided P value of less than .05 to be statistically significant [35].


    Literature Search

    The complete search process is presented in Figure 1. Table S1 in Multimedia Appendix 1 presents details of the literature search of 8327 papers retrieved from MEDLINE, Embase, and Web of Science electronic literature searches. After a full-text review, 7 of these papers were excluded, with specific details provided in Table S2 in Multimedia Appendix 1 [26,36-41]. A total of 12 studies met the prespecified inclusion criteria [5,42-52]. Table 1 presents the characteristics of the 12 included studies. In total, 5 studies validated the PA questionnaire [43,46,48,49,51]. Most of the included studies were conducted in Europe with a total of 6 studies [44,47-49,51,52]. Of the 12 included studies, only 2 focused on patients with type 1 diabetes [47,48], while the rest exclusively studied patients with type 2 diabetes; 4 studies limited the scope of PA to leisure-time PA [42,46,48,50].

    Table S3 in Multimedia Appendix 1 shows details of the confounding factors considered in each included study. In total, 4 studies detailed the patients’ CVD history [5,42,44,51], 7 studies considered social factors [5,42-45,50,51], and 4 studies took dietary factors into account [43,46,50,51]. The consideration of confounders varied among the studies, and more than half of the included studies adjusted the effect measure for all of the 5 following classic CVD risk factors: age, gender, smoking, dyslipidemia, and hypertension. A complete assessment of the quality of the literature is shown in Table S4 in Multimedia Appendix 1.

    ‎
    Figure 1. Study selection flowchart according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.
    Table 1. Details of characteristics of the included studies, including study region, follow-up duration, duration of diabetes, type of diabetes, and some basic information about patients.
    Author (year; area) Follow-up years, mean (SD) d_durationa (years), mean (SD) Age (years), mean (SD) PAb type (d_typec) PA_verifiedd BMI (kg/m2), mean (SD) Outcome
    Blomster et al (2013; 20+)e [5] 5 (—f) 7.9 (6.4) 65.8 (6.4) Total PA (2) Yes 28.3 (5.2) CVDg events
    Brown et al (2014; United States) [42] 9.2 (4.9) 10.9 (8.8) 65.5 (—) Total PA (2) No 29.51 (—) CVD mortality
    Chen et al (2022; China)e [43] 4.5 (—) 5 (—) 62.9 (—) Total PA (2) No 25.29 (—) CVD mortality or heart disease mortality or stroke mortality
    Enguita-Germán et al (2021; Kingdom of Spain) [44] 5 (—) 7.3 (—) 70.5 (—) Total PA (2) No 30.6 (—) CVD events
    Inoue et al (2020; United Mexican States)e [45] 8 (—) — (—) 70.3 (—) Total PA (2) No 29.17 (—) Nonfatal CVD events or fatal CVD event
    Sone et al (2013; Japan)e [46] 8.05 (—) 11.0 (7.1) 58.5 (—) LTPAh (2) No 23.0 (3.0) CHDi only, stroke only, or both
    Tielemans et al (2013; Europe)e [47] 7 (—) 13.6 (—) 32.7 (10.2) Total PA (1) No 23.59 (—) Total CVD events (men or women)
    Tikkanen-Dolenc et al (2017; Finland)e [48] 10.3 (3.4) 21.7 (12.4) 38.8 (12.4) LTPA (1) Yes 25.2 (3.6) CVD events
    Vepsäläinen et al (2010; Finland) [49] 18 (—) 7.8 (—) <60 (—) Total PA (2) Yes 29.2 (—) CVD mortality or CHD mortality
    Yen et al (2022; Taiwan [China])e [50] 17 (—) — (—) 60 (13) LTPA (2) Yes 24.7 (—) CVD mortality
    Yerramalla et al (2020; United Kingdom)e [51] 8.8 (6.1) — (—) 44.9 (6.0) Total PA (2) Yes — (—) CVD mortality
    Zethelius et al (2014; Switzerland)e [52] 4.8 (—) 5.7 (—) 59.9 (—) Total PA (2) No 30.04 (—) Fatal or nonfatal CVD or fatal or nonfatal CHD or fatal CVD

    ad_duration: duration of diabetes mellitus.

    bPA: physical activity.

    cd_type: types of diabetes mellitus.

    dPA_verified: validation of PA questionnaire.

    eThis study was used for the dose-response analysis between PA and outcomes.

    fNot available.

    gCVD: cardiovascular disease.

    hLTPA: leisure time physical activity.

    iCHD: coronary artery heart disease.

    Qualitative Assessment of the Association of High PA With CVD Risk

    Of the 12 included studies, 5 studies included multiple outcomes, such as coronary artery heart disease (CHD), stroke, and heart disease [43,45-47,49,52]. When the outcomes of one study were fatal or nonfatal CVD, fatal or nonfatal CHD, and fatal CVD, we chose fatal or nonfatal CVD for qualitative analysis because it had greater representation [52]. When the outcomes of the study were CHD or stroke and CHD and stroke, we chose CHD for qualitative analysis [46]. When the outcomes of the study were fatal CVD, heart disease mortality, and stroke mortality, we chose fatal CVD for qualitative analysis [43]. One study included 2 separate outcomes, fatal and nonfatal CVD events, and we combined the estimates using a fixed-effects model [45]. Specific information regarding the studies included in the qualitative analysis is provided in Table S5 in Multimedia Appendix 1.

    Figure 2 shows the forest plot for the risk estimate of CVD events in relation to PA in patients with diabetes. As heterogeneity was revealed by the I2 statistic (I2=72.9%; P<.001), a random effects model was used. The pooled RR of the CVD event was 0.62 (95% CI 0.51-0.73).

    Table 2 shows the results of the stratified analyses for the key study characteristics in addition to the results of meta-regression analyses testing strata difference. The predefined characteristics did not significantly alter the combined relationship between PA and the risk of CVD. A consistently lower risk of CVD events was observed across all strata.

    To assess publication bias, we visually inspected the funnel plots presented in Figure 3. Both sides of the funnel plot were essentially symmetrical, and the Egger test was used, and there was limited evidence for small-study effects (tX=1.13; df=10; P=.29), as shown in Figure S1 in Multimedia Appendix 1. The results of the subgroup analyses did not identify sources of heterogeneity but were consistent for the health benefits of PA, as shown in Figures S2-S10 in Multimedia Appendix 1. The results of the sensitivity analysis consistently supported our main findings, demonstrating the stability and reliability of the results, as shown in Figure S11 in Multimedia Appendix 1.

    ‎
    Figure 2. Forest plot illustrating the summary estimate of cardiovascular disease risk for individuals with diabetes in the highest versus lowest physical activity group along with the 95% CI. Study-specific estimates and the overall pooled estimate are depicted by circles and diamonds, respectively. Horizontal lines indicate the range of the 95% CI. The size of the squares represents the weight of each study, with larger squares indicating studies with greater weight [5,36-46]. RR: relative risk.
    Table 2. Stratified analyses of pooled RRa of cardiovascular disease morbidity comparing high versus low levels of PAb.
    Studies, n (%)RR (95% CI)Q statisticsI² (%)P value of heterogeneityMeta-regressionc
    Total120.62 (0.51-0.73)40.5872.90<.001—d
    Mean follow-up duration (years)
    ≤109 (75)0.61 (0.48-0.74)38.4379.20<.001Reference
    >103 (25)0.67 (0.52-0.82)0.760<.0010.64
    Type of diabetes
    Type 12 (17)0.79 (0.45-1.12)2.2956.30<.001Reference
    Type 210 (83)0.60 (0.48-0.72)35.4274.60<.0010.25
    Duration of diabetes (years)
    Not to mention3 (25)0.57 (0.40-0.75)3.0033.40<.001Reference
    ≤105 (42)0.60 (0.43-0.77)31.7187.40<.0010.34
    >104 (33)0.71 (0.54-0.89)3.288.50<.0010.98
    Mean age (years)
    <606 (50)0.60 (0.42-0.79)15.6168<.001Reference
    ≥606 (50)0.64 (0.52-0.77)16.6368<.0010.77
    PA type
    LTPAe4 (33)0.68 (0.52-0.83)1.090<.001Reference
    Total PA8 (67)0.61 (0.47-0.74)38.0381.60<.0010.55
    Men (%)
    ≤506 (50)0.61 (0.48-0.74)9.7748.80<.001Reference
    >506 (50)0.62 (0.44-0.80)30.6683.70<.0010.88
    Validation of PA questionnaire
    Yes5 (42)0.54 (0.43-0.65)3.460<.001Reference
    No7 (58)0.66 (0.51-0.82)36.1783.40<.0010.48
    Area
    Asia3 (25)0.62 (0.38-0.87)4.5455.90<.001Reference
    Europe6 (50)0.61 (0.44-0.79)25.3980.30<.0010.63
    North America2 (17)0.54 (0.42-0.67)0.130<.0010.49
    Mixtures1 (8)0.81 (0.67-0.95)0–<.0010.68
    BMIf (kg/m2)
    <252 (17)0.90 (0.63-1.18)0.450.50Reference
    ≥258 (67)0.61 (0.50-0.72)14.6152.10.040.31
    ≥302 (17)0.55 (0.23-0.88)18.0194.40<.0010.35

    aRR: relative risk.

    bPA: physical activity.

    cMeta-regression: represents test for significance of the study modification across strata.

    dNot available.

    eLTPA: leisure-time physical activity.

    fBMI: overweight is defined as BMI ≥25 kg/m2, and obese is defined as BMI ≥30 kg/m2.

    ‎
    Figure 3. Funnel plot assessing publication bias for the meta-analysis of prospective studies on the relationship between physical activity categories (the highest vs the lowest) and cardiovascular disease risk in individuals with diabetes. RR: relative risk.

    Dose-Response Relationship Between PA and CVD Events and Mortality

    Specific information regarding the studies included in the quantitative analysis is provided in Tables S6-S8 in Multimedia Appendix 1. The log RR of CVD events and mortality against weekly PA in terms of MET-hours in patients with diabetes are described in the linear and spline regression curves (Figure 4). The linear regression model results indicate that a 10 MET-hours per week incrementally higher PA was associated with a 19% (95% CI 11.6-25.7) and a 6.9% (95% CI 4.5-9.3) reduction in total CVD risk and risk of CVD mortality, respectively. The results of the spline regression analysis demonstrated that the relationship between PA and CVD morbidity and mortality was nonlinear (both Pnonlinearity<.001). While there was a limited reduction in the risk of total CVD as PA levels increased, there were additional reductions in the risk of CVD mortality beyond PA levels of 20 MET-hours per week.

    ‎
    Figure 4. Relationship between weekly PA and relative risk of (A) CVD events and (B) CVD mortality in individuals with diabetes. Spline regression curves depicting the relationship between PA and CVD risk are presented. The solid line represents a log-linear relationship, while the dashed lines indicate the upper and lower limits of the 95% CI. A distinct inflection point is observed at 20 MET-hours of movement per week. The graph exhibits an overall downward trend. CVD: cardiovascular disease; PA: physical activity.

    Overview

    The global incidence of diabetes, particularly type 2 diabetes, is increasing annually. Patients with diabetes often experience multiple complications, and in severe cases, these complications can cause premature death [53]. Therefore, it is essential to actively guide patients with diabetes toward a healthy lifestyle, which includes regular PA, to prevent cardiovascular complications and other adverse outcomes [54,55]. A healthy lifestyle is inseparable from active exercise, essential for health promotion and well-being enhancement. Exercise plays an important role as a preventive strategy against various chronic diseases, including CVD, stroke, diabetes, osteoporosis, and obesity, and improves the quality of life in terms of mental health [56,57]. It is recommended that individuals with type 2 diabetes engage in regular PA and reduce their sedentary time by taking breaks between sedentary activities.

    Principal Findings

    This study aimed to synthesize evidence from prospective studies to elucidate the relationship between PA and CVD risk in patients with diabetes. The main finding of this study revealed a significant inverse correlation between regular PA and the risk of CVD in individuals with diabetes. These results align with previous studies that have shown the positive impact of exercise on glucose levels, β cell function, insulin sensitivity, vascular function, and gut microbiota, contributing to the healthy management of diabetes and reducing the risk of CVD [25].

    The results of this study revealed that the trend of decreasing CVD morbidity and mortality slowed after the inflection point and leveled off with increasing PA. It is noteworthy that this slowing trend did not affect the positive effect of PA on CVD risk. Previous studies have suggested that the health effects of high doses of PA are not yet clear and may even be harmful to the cardiovascular system [58]. However, in this study, no negative effects were observed, and any amount of exercise was beneficial in reducing CVD risk for individuals with diabetes.

    Limitations

    This study has some limitations. First, in most of the included cohort studies, PA information was mainly obtained using questionnaires, which were differentially applied in different studies, and the findings may have been affected by the potential recall bias. Second, some studies included different end-point outcomes, such as CHD, CHD mortality, and stroke; however, we did not analyze them separately either qualitatively or quantitatively, due to the relatively small number of studies on these CVD subtypes. Third, only a few of the studies included in this review addressed leisure-time PA, and future studies may be needed to further elucidate the effects of specific types of PA on cardiovascular risk in patients with diabetes. Finally, the inclusion of different subtypes of diabetes among the study participants. Type 1 diabetes is typically characterized by autoimmune destruction of pancreatic β cells, resulting from the immune system attacking insulin-producing cells, and is associated with both genetic and environmental factors [59]. In contrast, type 2 diabetes is attributed to insulin resistance and inadequate insulin secretion, closely linked to obesity, unhealthy lifestyles, and genetic factors [60]. Therefore, variations in physiological and pathological profiles between the 2 types may lead to disparate cardiovascular responses to PA. However, according to previous studies, patients with both type 1 and type 2 diabetes benefit from engaging in appropriate exercise routines [57,61-65]. Consequently, we aim to analyze the overall health benefits of PA for all patients with diabetes. Although the FS3 results indicate that different types of diabetes are potential factors causing heterogeneity, they indeed demonstrate health benefits for both types of patients. Given this limitation, we intend to conduct future studies that are more tailored to different subtypes of patients with diabetes as much as possible.

    Comparison to Prior Work

    It is worth noting that while previous studies have explored the link between PA and CVD, this study takes a more focused approach to cardiovascular health [66-68]. We conducted thorough analyses, separately examining the risks of CVD and CVD mortality. Additionally, we included relevant research conducted from 2010 to the present, enhancing the timeliness of our findings. Therefore, our research retains significant clinical value.

    Conclusions

    This study demonstrated a dose-response relationship between increased PA and decreased risk of CVD morbidity and mortality in patients with diabetes, particularly type 2 diabetes. The observed PA threshold was consistent with the recommended level for the general population, indicating that gradually increasing PA levels from a sedentary state to the recommended guidelines can significantly reduce the burden of CVD in patients with diabetes. These findings support the development and implementation of policies to promote PA among patients with diabetes, particularly those with type 2 diabetes.

    Acknowledgments

    This work was supported by the National Natural Science Foundation of China (grants 31971097 and 32271226), the Shanghai Municipal Science and Technology Committee of Shanghai Outstanding Academic Leaders Plan (grant 21XD1403200), and the Humanities and Social Sciences Youth Fund of the Ministry of Education (grant 21YJC890030). RW and HT are cocorresponding authors of this paper.

    Data Availability

    The data sets generated and analyzed during this study are available from the corresponding author on reasonable request.

    Authors' Contributions

    All the authors involved in drafting or revising the paper and approved of the submitted version. YC drafted the manuscript. HT, GC, and RW helped conceive the design and made edits and comments to the manuscript. YC, XJ, and GC carried out the literature search and helped in drafting the manuscript. All authors have read and approved the final manuscript.

    Conflicts of Interest

    None declared.

    Multimedia Appendix 1

    Search strategy, study selection, confounders, bias assessment, data summary, subgroup analyses, and sensitivity analysis.

    DOCX File , 2277 KB
    1. Armstrong DG, Tan T, Boulton AJM, Bus SA. Diabetic foot ulcers: a review. JAMA. 2023;330(1):62-75. [CrossRef] [Medline]
    2. Song SH. Young-onset type 2 diabetes and retinopathy: evidence of an adverse phenotype. BMJ Open Diabetes Res Care. 2024;12(1):e003899. [FREE Full text] [CrossRef] [Medline]
    3. Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson C. Diagnosis and management of central diabetes insipidus in adults. J Clin Endocrinol Metab. 2022;107(10):2701-2715. [FREE Full text] [CrossRef] [Medline]
    4. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. [CrossRef] [Medline]
    5. Blomster JI, Chow CK, Zoungas S, Woodward M, Patel A, Poulter NR, et al. The influence of physical activity on vascular complications and mortality in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(11):1008-1012. [CrossRef] [Medline]
    6. Campbell NR, Ordunez P, Giraldo G, Rodriguez Morales YA, Lombardi C, Khan T, et al. WHO HEARTS: a global program to reduce cardiovascular disease burden: experience implementing in the Americas and opportunities in Canada. Can J Cardiol. 2021;37(5):744-755. [CrossRef] [Medline]
    7. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1835. [FREE Full text] [CrossRef] [Medline]
    8. Jung E, Kong SY, Ro YS, Ryu HH, Shin SD. Serum cholesterol levels and risk of cardiovascular death: a systematic review and a dose-response meta-analysis of prospective cohort studies. Int J Environ Res Public Health. 2022;19(14):8272. [FREE Full text] [CrossRef] [Medline]
    9. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022;23(6):3346. [FREE Full text] [CrossRef] [Medline]
    10. Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20(10):685-695. [CrossRef] [Medline]
    11. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan R, Antunes M, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. [CrossRef] [Medline]
    12. Cardiovascular diseases (CVDs). World Health Organization. 2021. URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [accessed 2024-04-08]
    13. World Heart Report 2023: confronting the world's number one killer. World Heart Federation. 2023. URL: https://heartreport23.world-heart-federation.org/ [accessed 2024-04-08]
    14. Barengo NC, Antikainen R, Borodulin K, Harald K, Jousilahti P. Leisure-time physical activity reduces total and cardiovascular mortality and cardiovascular disease incidence in older adults. J Am Geriatr Soc. 2017;65(3):504-510. [CrossRef] [Medline]
    15. Martinez-Gomez D, Cabanas-Sanchez V, Yu T, Rodriguez-Artalejo F, Ding D, Lee I, et al. Long-term leisure-time physical activity and risk of all-cause and cardiovascular mortality: dose-response associations in a prospective cohort study of 210 327 Taiwanese adults. Br J Sports Med. 2022;56(16):919-926. [CrossRef] [Medline]
    16. Saint-Maurice PF, Coughlan D, Kelly SP, Keadle SK, Cook MB, Carlson SA, et al. Association of leisure-time physical activity across the adult life course with all-cause and cause-specific mortality. JAMA Netw Open. 2019;2(3):e190355. [FREE Full text] [CrossRef] [Medline]
    17. Watts EL, Matthews CE, Freeman JR, Gorzelitz JS, Hong HG, Liao LM, et al. Association of leisure time physical activity types and risks of all-cause, cardiovascular, and cancer mortality among older adults. JAMA Netw Open. 2022;5(8):e2228510. [FREE Full text] [CrossRef] [Medline]
    18. Levesque C. Therapeutic lifestyle changes for diabetes mellitus. Nurs Clin North Am. 2017;52(4):679-692. [CrossRef] [Medline]
    19. Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee D, et al. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res. 2015;117(2):207-219. [FREE Full text] [CrossRef] [Medline]
    20. Olver TD, Laughlin MH, Padilla J. Exercise and vascular insulin sensitivity in the skeletal muscle and brain. Exerc Sport Sci Rev. 2019;47(2):66-74. [FREE Full text] [CrossRef] [Medline]
    21. Qiu S, Cai X, Yin H, Sun Z, Zügel M, Steinacker JM, et al. Exercise training and endothelial function in patients with type 2 diabetes: a meta-analysis. Cardiovasc Diabetol. 2018;17(1):64. [FREE Full text] [CrossRef] [Medline]
    22. Huebschmann AG, Huxley RR, Kohrt WM, Zeitler P, Regensteiner JG, Reusch JEB. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia. 2019;62(10):1761-1772. [FREE Full text] [CrossRef] [Medline]
    23. Sharma S, Pelliccia A, Gati S. The 'ten commandments' for the 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):6-7. [CrossRef] [Medline]
    24. WHO guidelines on physical activity and sedentary behaviour. World Health Organization. 2020. URL: https://www.who.int/publications/i/item/9789240015128 [accessed 2023-01-02]
    25. Jung I, Kwon H, Park SE, Han KD, Park YG, Rhee EJ, et al. Changes in patterns of physical activity and risk of heart failure in newly diagnosed diabetes mellitus patients. Diabetes Metab J. 2022;46(2):327-336. [FREE Full text] [CrossRef] [Medline]
    26. Barakat A, Williams KM, Prevost AT, Kinmonth A, Wareham NJ, Griffin SJ, et al. Changes in physical activity and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort. Diabet Med. 2013;30(2):233-238. [FREE Full text] [CrossRef] [Medline]
    27. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. [CrossRef] [Medline]
    28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. [FREE Full text] [CrossRef] [Medline]
    29. Van Itallie TB. Health implications of overweight and obesity in the United States. Ann Intern Med. 1985;103(6 ( Pt 2)):983-988. [CrossRef] [Medline]
    30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. [FREE Full text] [CrossRef] [Medline]
    31. Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011;124(7):789-795. [FREE Full text] [CrossRef] [Medline]
    32. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Tudor-Locke C, et al. 2011 Compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43(8):1575-1581. [CrossRef] [Medline]
    33. Liu X, Zhang D, Liu Y, Sun X, Han C, Wang B, et al. Dose-response association between physical activity and incident hypertension: a systematic review and meta-analysis of cohort studies. Hypertension. 2017;69(5):813-820. [CrossRef] [Medline]
    34. Smith AD, Crippa A, Woodcock J, Brage S. Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies. Diabetologia. 2016;59(12):2527-2545. [FREE Full text] [CrossRef] [Medline]
    35. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119-1129. [CrossRef] [Medline]
    36. Funck KL, Laugesen E, Høyem P, Fleischer J, Cichosz SL, Christiansen JS, et al. Low physical activity is associated with increased arterial stiffness in patients recently diagnosed with type 2 diabetes. Am J Hypertens. 2016;29(7):882. [CrossRef] [Medline]
    37. Minnebeck K, Vorona E, Zinn S, Gellner R, Hinder J, Brand SM, et al. Four weeks of high-intensity interval training (HIIT) improve the cardiometabolic risk profile of overweight patients with type 1 diabetes mellitus (T1DM). Eur J Sport Sci. 2021;21(8):1193-1203. [FREE Full text] [CrossRef] [Medline]
    38. Glenn KR, Slaughter JC, Fowke JH, Buchowski MS, Matthews CE, Signorello LB, et al. Physical activity, sedentary behavior and all-cause mortality among blacks and whites with diabetes. Ann Epidemiol. 2015;25(9):649-655. [FREE Full text] [CrossRef] [Medline]
    39. Cirilli I, Silvestri S, Marcheggiani F, Olivieri F, Galeazzi R, Antonicelli R, et al. Three months monitored metabolic fitness modulates cardiovascular risk factors in diabetic patients. Diabetes Metab J. 2019;43(6):893-897. [FREE Full text] [CrossRef] [Medline]
    40. Strelitz J, Ahern AL, Long GH, Boothby CE, Wareham NJ, Griffin SJ. Changes in behaviors after diagnosis of type 2 diabetes and 10-year incidence of cardiovascular disease and mortality. Cardiovasc Diabetol. 01, 2019;18(1):98. [FREE Full text] [CrossRef] [Medline]
    41. Savory LA, Griffin SJ, Williams KM, Prevost AT, Kinmonth A, Wareham NJ, et al. Changes in diet, cardiovascular risk factors and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort. Diabet Med. 2014;31(2):148. [FREE Full text] [CrossRef] [Medline]
    42. Brown RE, Riddell MC, Macpherson AK, Canning KL, Kuk JL. All-cause and cardiovascular mortality risk in U.S. adults with and without type 2 diabetes: influence of physical activity, pharmacological treatment and glycemic control. J Diabetes Complications. 2014;28(3):311-315. [CrossRef] [Medline]
    43. Chen Y, Su J, Qin Y, Luo P, Shen C, Pan E, et al. Fresh fruit consumption, physical activity, and five-year risk of mortality among patients with type 2 diabetes: a prospective follow-up study. Nutr Metab Cardiovasc Dis. 2022;32(4):878-888. [CrossRef] [Medline]
    44. Enguita-Germán M, Tamayo I, Galbete A, Librero J, Cambra K, Ibáñez-Beroiz B. Effect of physical activity on cardiovascular event risk in a population-based cohort of patients with type 2 diabetes. Int J Environ Res Public Health. 2021;18(23):12370. [FREE Full text] [CrossRef] [Medline]
    45. Inoue K, Mayeda ER, Paul KC, Shih IF, Yan Q, Yu Y, et al. Mediation of the associations of physical activity with cardiovascular events and mortality by diabetes in older Mexican Americans. Am J Epidemiol. 2020;189(10):1124-1133. [FREE Full text] [CrossRef] [Medline]
    46. Sone H, Tanaka S, Tanaka S, Suzuki S, Seino H, Hanyu O, et al. Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS). Diabetologia. 2013;56(5):1021-1030. [CrossRef] [Medline]
    47. Tielemans SMAJ, Soedamah-Muthu SS, De Neve M, Toeller M, Chaturvedi N, Fuller JH, et al. Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2013;56(1):82-91. [CrossRef] [Medline]
    48. Tikkanen-Dolenc H, Wadén J, Forsblom C, Harjutsalo V, Thorn LM, Saraheimo M, et al. Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes. Diabetologia. 2017;60(3):574-580. [CrossRef] [Medline]
    49. Vepsäläinen T, Soinio M, Lehto S, Juutilainen A, Laakso M, Rönnemaa T. Proteinuria modifies the effects of physical activity on total and cardiovascular disease mortality rates in patients with type 2 diabetes. Diabetologia. 2010;53(9):1886-1889. [CrossRef] [Medline]
    50. Yen Y, Wang C, Chen Y, Hsu L, Hung K, Chen L, et al. Leisure-time physical activity and mortality risk in type 2 diabetes: a nationwide cohort study. Diabetes Metab. 2022;48(6):101378. [CrossRef] [Medline]
    51. Yerramalla MS, Fayosse A, Dugravot A, Tabak AG, Kivimäki M, Singh-Manoux A, et al. Association of moderate and vigorous physical activity with incidence of type 2 diabetes and subsequent mortality: 27 year follow-up of the Whitehall II study. Diabetologia. 2020;63(3):537-548. [FREE Full text] [CrossRef] [Medline]
    52. Zethelius B, Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Cederholm J, Swedish National Diabetes Register. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register. Eur J Prev Cardiol. 2014;21(2):244-251. [CrossRef] [Medline]
    53. MacPherson M, Cranston K, Locke S, Vis-Dunbar M, Jung ME. Diet and exercise interventions for individuals at risk for type 2 diabetes: a scoping review protocol. BMJ Open. 2020;10(11):e039532. [FREE Full text] [CrossRef] [Medline]
    54. Karstoft K, Pedersen BK. Exercise and type 2 diabetes: focus on metabolism and inflammation. Immunol Cell Biol. 2016;94(2):146-150. [CrossRef] [Medline]
    55. Turner G, Quigg S, Davoren P, Basile R, McAuley SA, Coombes JS. Resources to guide exercise specialists managing adults with diabetes. Sports Med Open. 2019;5(1):20. [FREE Full text] [CrossRef] [Medline]
    56. Villareal DT, Aguirre L, Gurney AB, Waters DL, Sinacore DR, Colombo E, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. May 18, 2017;376(20):1943-1955. [FREE Full text] [CrossRef] [Medline]
    57. Kanaley JA, Colberg SR, Corcoran MH, Malin SK, Rodriguez NR, Crespo CJ, et al. Exercise/physical activity in individuals with type 2 diabetes: a consensus statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2022;54(2):353-368. [FREE Full text] [CrossRef] [Medline]
    58. Rao P, Hutter AM, Baggish AL. The limits of cardiac performance: can too much exercise damage the heart? Am J Med. 2018;131(11):1279-1284. [CrossRef] [Medline]
    59. Gillespie KM. Type 1 diabetes: pathogenesis and prevention. CMAJ. 2006;175(2):165-170. [FREE Full text] [CrossRef] [Medline]
    60. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239-2251. [CrossRef] [Medline]
    61. Balducci S, Sacchetti M, Haxhi J, Orlando G, D'Errico V, Fallucca S, et al. Physical exercise as therapy for type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014:13-23. [CrossRef] [Medline]
    62. Lu X, Zhao C. Exercise and type 1 diabetes. Adv Exp Med Biol. 2020;1228:107-121. [CrossRef] [Medline]
    63. McCarthy M, Ilkowitz J, Zheng Y, Vaughan Dickson V. Exercise and self-management in adults with type 1 diabetes. Curr Cardiol Rep. 2022;24(7):861-868. [CrossRef] [Medline]
    64. Riddell MC, Peters AL. Exercise in adults with type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19(2):98-111. [CrossRef] [Medline]
    65. Sampath Kumar A, Maiya AG, Shastry B, Vaishali K, Ravishankar N, Hazari A, et al. Exercise and insulin resistance in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Phys Rehabil Med. 2019;62(2):98-103. [FREE Full text] [CrossRef] [Medline]
    66. Garcia L, Pearce M, Abbas A, Mok A, Strain T, Ali S, et al. Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies. Br J Sports Med. 2023;57(15):979-989. [FREE Full text] [CrossRef] [Medline]
    67. Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, et al. Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch Intern Med. 2012;172(17):1285-1295. [CrossRef] [Medline]
    68. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc. 2016;5(9):e002495. [FREE Full text] [CrossRef] [Medline]

    ‎
    CHD: coronary artery heart disease
    CVD: cardiovascular disease
    MET: metabolic equivalent of task
    PA: physical activity
    RR: relative risk

    Edited by A Mavragani; submitted 06.11.23; peer-reviewed by A Arbabisarjou, B Lai, J Li, Y Ma, H Yuan, S Li; comments to author 05.04.24; revised version received 11.04.24; accepted 23.05.24; published 19.08.24.

    Copyright

    ©Yang Chen, Xingsheng Jin, Guochong Chen, Ru Wang, Haili Tian. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 19.08.2024.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on https://publichealth.jmir.org, as well as this copyright and license information must be included.